NVP-BVB808

NVP-BVB808 (11 individual concentrations; 72 h) potently inhibits proliferation of JAK2-mutant CHRF-288-11, SET-2, and UKE-1 cells with GI₅₀ values of 0.15 μM, 0.25 μM, and 0.22 μM respectively after 72 hours, shows weaker activity against HEL cells (GI₅₀ = 2.13 μM), and inhibits proliferation of BCR-ABL-positive and JAK2 wild-type cell lines only at higher concentrations (GI₅₀ = 0.73-3.20 μM)^[1].
NVP-BVB808 (72 h) induces apoptosis in CHRF-288-11, SET-2, HEL, Lama-87, KU-812, BV173, K562, and KCL-22 cells, with the highest potency against CHRF-288-11 cells (IC₅₀ = 0.3 μM) and decreasing potency across the remaining cell lines^[1].
NVP-BVB808 (0-1 μM; 30 min) potently inhibits STAT5a phosphorylation in JAK2-mutant SET-2, and HEL cells at concentrations as low as 0.05 μM after 30 minutes, while showing minimal effect on BCR-ABL-positive K562 and KCL-22 cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.